1
|
Song G, Chang H, Mu N. Image testing based on biomedical drug loading in cardiovascular drug care simulation for coronary heart disease. Med Eng Phys 2024; 126:104150. [PMID: 38621849 DOI: 10.1016/j.medengphy.2024.104150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 02/28/2024] [Accepted: 03/09/2024] [Indexed: 04/17/2024]
Abstract
Coronary heart disease is a common cardiovascular disease, and its therapeutic effect is affected by the distribution and absorption of drugs in the body. Biomedical drug-carrying image testing technology can provide a quantitative assessment of drug distribution and absorption in the body. This study aims to explore the application of biomedical drug-carrying image testing technology in the simulation of cardiovascular drug care in coronary heart disease, so as to provide reference for the optimization of drug treatment plan and individualized treatment. The study collected clinical data and medication regiments of patients with coronary heart disease. Then, the imaging examination of patients was carried out by selecting appropriate drug loading markers using the biomedical drug loading image examination technology. Then quantitative analysis was used to process the image data to quantitatively evaluate the distribution and absorption of drugs in the cardiovascular system. The quantitative data of drug distribution and absorption in patients with coronary heart disease have been obtained successfully by means of biomedical imaging. These data reveal the dynamic changes of drugs in the cardiovascular system, and help doctors optimize drug therapy, improve treatment effectiveness, and achieve personalized treatment.
Collapse
Affiliation(s)
- Guifang Song
- Department of Cardiology, Yantai Yuhuangding Hospital, Yantai 264000, China
| | - Huili Chang
- Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Yantai 264000, China
| | - Nv Mu
- Department of Neurology, Yantai Yuhuangding Hospital, Yantai 264000, China.
| |
Collapse
|
2
|
Yasunaga T, Fukuoka T, Yamaguchi A, Ogawa N, Yamamoto H. Microtaggant Technology for Ensuring Traceability of Pharmaceutical Formulations: Potential for Anti-counterfeiting Measures, Distribution and Medication Management. YAKUGAKU ZASSHI 2022; 142:1255-1265. [DOI: 10.1248/yakushi.22-00147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Toshiya Yasunaga
- Laboratory of Pharmaceutical Engineering, School of Pharmacy, Aichi Gakuin University
| | | | - Akinobu Yamaguchi
- Laboratory of Advanced Science and Technology for Industry, University of Hyogo
| | - Noriko Ogawa
- Laboratory of Pharmaceutical Engineering, School of Pharmacy, Aichi Gakuin University
| | - Hiromitsu Yamamoto
- Laboratory of Pharmaceutical Engineering, School of Pharmacy, Aichi Gakuin University
| |
Collapse
|
3
|
Pettinau F, Manca I, Manca I, Pittau B. Rapid Approach for Pharmaceutical Quality Evaluation and Comparison. ChemistrySelect 2022. [DOI: 10.1002/slct.202200712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Francesca Pettinau
- Institute of Translational Pharmacology National Research Council 09010 Pula CA Italy
| | - Ilaria Manca
- Institute of Translational Pharmacology National Research Council 09010 Pula CA Italy
| | - Ilaria Manca
- Institute of Translational Pharmacology National Research Council 09010 Pula CA Italy
| | - Barbara Pittau
- Institute of Translational Pharmacology National Research Council 09010 Pula CA Italy
| |
Collapse
|
4
|
Ahmed J, Modica de Mohac L, Mackey TK, Raimi-Abraham BT. A critical review on the availability of substandard and falsified medicines online: Incidence, challenges and perspectives. THE JOURNAL OF MEDICINE ACCESS 2022; 6:23992026221074548. [PMID: 36204527 PMCID: PMC9413502 DOI: 10.1177/23992026221074548] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Accepted: 01/04/2022] [Indexed: 11/17/2022]
Abstract
Simultaneous expansion of the Internet and increased globalisation of the
pharmaceutical industry have meant medication can be accessed transnationally
from both legal and illicit sources. This has coincided with the rise of
substandard and falsified medicines (SFMs) online. These products fail to meet
regulatory or quality standards and/or are constituted with substandard
ingredients, causing undesired pharmacological effects, including possible
injury and death. This review aimed to identify original research studies that
examined characteristics of SFM online sales, attitudes towards purchasing
medicines online and strategies to address this drug safety challenge. Keywords
of ‘Substandard’ and ‘Falsified’/‘Counterfeit’ and ‘Medicines’/‘Drugs’ and
‘Online’/‘Internet’ were searched using Web of Knowledge and PubMed databases.
Resulting literature, which satisfied the study’s inclusion criteria, was
included in the review, and the findings from each paper were assessed. From an
initial 185 literature articles, 7 were eligible according to the inclusion
criteria to be reviewed. These articles identified studies testing SFMs
purchased online, surveys of attitudes and knowledge about SFMs online, and
website content analysis to detect illegal online sales. Challenges identified
were lack of knowledge and awareness among consumers and physicians, in addition
to the use of direct-to-consumer-advertising, via Internet platforms and social
media, providing easy access to SFMs. Despite this, medicine authentication
technology, website verification approaches and new detection methods were
identified as potential solutions specific to online SFM sales. To address
online sales of SFMs, more robust research, greater awareness/educational
programmes, analytical detection methods and more stringent online global
governance are required.
Collapse
Affiliation(s)
- Jamee Ahmed
- Institute of Pharmaceutical Sciences, School of Cancer and Pharmaceutical Science, King’s College London, London, UK
| | - Laura Modica de Mohac
- Institute of Pharmaceutical Sciences, School of Cancer and Pharmaceutical Science, King’s College London, London, UK
| | - Tim K Mackey
- Department of Anesthesiology and Division of Infectious Diseases and Global Public Health, School of Medicine, UC San Diego, La Jolla, CA, USA
| | | |
Collapse
|
5
|
Sakuda M, Yoshida N, Koide T, Keila T, Kimura K, Tsuboi H. Clarification of the internal structure and factors of poor dissolution of substandard roxithromycin tablets by near-infrared chemical imaging. Int J Pharm 2021; 596:120232. [PMID: 33484929 PMCID: PMC7910273 DOI: 10.1016/j.ijpharm.2021.120232] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 12/23/2020] [Accepted: 12/29/2020] [Indexed: 12/18/2022]
Abstract
The spread of substandard and falsified medicines has become a global problem, especially in low- and middle-income countries (LMICs). Previously, we found that some tablets containing the same active ingredient had large differences in their dissolution even though their contents were comparable. In this study, we investigated the poor dissolution of roxithromycin tablets using near-infrared chemical imaging (NIR-CI) to visualize the internal tablet structure. Roxithromycin tablets collected in LMICs and the pioneer product Rulid® as a reference were cut to a flat surface for analysis. NIR spectral data were normalized, and a principal component analysis was performed to create a tablet internal structure image. For Rulid®, the differences between the spectra with high and low scores were small, and well-defined aggregation of ingredients was not observed. However, large differences in the scores were found for roxithromycin tablets manufactured in some LMICs, and non-uniformity of ingredient distribution and aggregation were observed. Additionally, some pharmaceutical excipients, such as starch or magnesium stearate, were found in certain aggregates by comparing NIR spectra. The NIR-CI results showed some excipients existed as large aggregates, which indicated that the ingredients were not evenly mixed in the roxithromycin tablet, and this contributed to its poor dissolution.
Collapse
Affiliation(s)
- Mirai Sakuda
- Clinical Pharmacy and Healthcare Sciences, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Naoko Yoshida
- AI Hospital/Macro Signal Dynamics Research and Development Center, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan.
| | - Tatsuo Koide
- Division of Drugs, National Institute of Health Sciences, Kawasaki 210-9501, Japan
| | - Tep Keila
- National Health Product Quality Control Center, Ministry of Health, Phnom Penh 12110, Cambodia
| | - Kazuko Kimura
- Medi-Quality Security Institute, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Hirohito Tsuboi
- Clinical Pharmacy and Healthcare Sciences, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| |
Collapse
|
6
|
Vickers S, Bernier M, Zambrzycki S, Fernandez FM, Newton PN, Caillet C. Field detection devices for screening the quality of medicines: a systematic review. BMJ Glob Health 2018; 3:e000725. [PMID: 30233826 PMCID: PMC6135480 DOI: 10.1136/bmjgh-2018-000725] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Revised: 06/20/2018] [Accepted: 06/24/2018] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Poor quality medicines have devastating consequences. A plethora of innovative portable devices to screen for poor quality medicines has become available, leading to hope that they could empower medicine inspectors and enhance surveillance. However, information comparing these new technologies is woefully scarce. METHODS We undertook a systematic review of Embase, PubMed, Web of Science and SciFinder databases up to 30 April 2018. Scientific studies evaluating the performances/abilities of portable devices to assess any aspect of the quality of pharmaceutical products were included. RESULTS Forty-one devices, from small benchtop spectrometers to 'lab-on-a-chip' single-use devices, with prices ranging from US$20 000, were included. Only six devices had been field-tested (GPHF-Minilab, CD3/CD3+, TruScan RM, lateral flow dipstick immunoassay, CBEx and Speedy Breedy). The median (range) number of active pharmaceutical ingredients (APIs) assessed per device was only 2 (1-20). The majority of devices showed promise to distinguish genuine from falsified medicines. Devices with the potential to assay API (semi)-quantitatively required consumables and were destructive (GPHF-Minilab, PharmaChk, aPADs, lateral flow immunoassay dipsticks, paper-based microfluidic strip and capillary electrophoresis), except for spectroscopic devices. However, the 10 spectroscopic devices tested for their abilities to quantitate APIs required processing complex API-specific calibration models. Scientific evidence of the ability of the devices to accurately test liquid, capsule or topical formulations, or to distinguish between chiral molecules, was limited. There was no comment on cost-effectiveness and little information on where in the pharmaceutical supply chain these devices could be best deployed. CONCLUSION Although a diverse range of portable field detection devices for medicines quality screening is available, there is a vitally important lack of independent evaluation of the majority of devices, particularly in field settings. Intensive research is needed in order to inform national medicines regulatory authorities of the optimal choice of device(s) to combat poor quality medicines.
Collapse
Affiliation(s)
- Serena Vickers
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos
- Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
- Infectious Diseases Data Observatory (IDDO)/Worldwide Antimalarial Resistance Network (WWARN), University of Oxford, Oxford, UK
| | - Matthew Bernier
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia, USA
- Campus Chemical Instrument Center Mass Spectrometry and Proteomics Facility, The Ohio State University, Columbus, Ohio, USA
| | - Stephen Zambrzycki
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia, USA
| | - Facundo M Fernandez
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia, USA
| | - Paul N Newton
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos
- Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
- Infectious Diseases Data Observatory (IDDO)/Worldwide Antimalarial Resistance Network (WWARN), University of Oxford, Oxford, UK
| | - Céline Caillet
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos
- Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
- Infectious Diseases Data Observatory (IDDO)/Worldwide Antimalarial Resistance Network (WWARN), University of Oxford, Oxford, UK
| |
Collapse
|
7
|
Venhuis BJ, Oostlander AE, Giorgio DD, Mosimann R, du Plessis I. Oncology drugs in the crosshairs of pharmaceutical crime. Lancet Oncol 2018; 19:e209-e217. [DOI: 10.1016/s1470-2045(18)30101-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Revised: 12/20/2017] [Accepted: 12/21/2017] [Indexed: 11/29/2022]
|
8
|
Hattori Y, Seko Y, Peerapattana J, Otsuka K, Sakamoto T, Otsuka M. Rapid identification of oral solid dosage forms of counterfeit pharmaceuticals by discrimination using near-infrared spectroscopy. Biomed Mater Eng 2017; 29:1-14. [PMID: 29254069 DOI: 10.3233/bme-171708] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Since it can take an enormous amount of time and cost to discriminate counterfeit medicines by using conventional methods, counterfeit medicines has been spread in the world markets. OBJECTIVE The purpose of this study was to develop a rapid and simple analytical method to discriminate counterfeit drugs using near infrared (NIR) spectroscopy. METHODS Seven types of brand name tablet and generic tablets containing atorvastatin calcium sesquihydrate (AT) preparations were used as simulated counterfeit medicines. NIR spectra of 35 AT tablet products were measured using a diffuse reflection method. RESULTS The NIR spectral data were analyzed by principal component analysis (PCA). The PCA results suggested that the model had sufficient accuracy to discriminate the 7 types for AT tablets. The NIR spectral data were also analyzed using a soft independent modeling of class analogy (SIMCA) method. Predicting the classification of the AT tablet samples was performed based on all the validated AT tablet data using the SIMCA model, and the probability of classification of 7 types was 100%. The discrimination power spectrum of the SIMCA model indicated significant patterns based on diluents. CONCLUSIONS The PCA and SIMCA classification of the AT tablets were depended on the major excipient combinations.
Collapse
Affiliation(s)
- Yusuke Hattori
- Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishi-Tokyo, 202-8585, Japan
| | - Yurie Seko
- Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishi-Tokyo, 202-8585, Japan
| | - Jomjai Peerapattana
- Center for Research and Development of Herbal Health Products, Faculty of Pharmaceutical Sciences, No.123, Naimaung, Muang Khon Kaen University, Khon Kaen, 40002, Thailand
| | - Kuniko Otsuka
- Yokohama College of Pharmacy, 601 Matano-cho, Totsuka-ku, Yokohama 245-0066, Japan
| | - Tomoaki Sakamoto
- Division of Drugs, National Institute of Health Sciences, Kamiyoga 1-18-1, Setagaya-ku, Tokyo 158-8501, Japan
| | - Makoto Otsuka
- Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishi-Tokyo, 202-8585, Japan
| |
Collapse
|
9
|
Rebiere H, Guinot P, Chauvey D, Brenier C. Fighting falsified medicines: The analytical approach. J Pharm Biomed Anal 2017; 142:286-306. [PMID: 28531832 DOI: 10.1016/j.jpba.2017.05.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Revised: 05/02/2017] [Accepted: 05/04/2017] [Indexed: 01/27/2023]
Abstract
Given the harm to human health, the fight against falsified medicines has become a priority issue that involves numerous actors. Analytical laboratories contribute by performing analyses to chemically characterise falsified samples and assess their hazards for patients. A wide range of techniques can be used to obtain individual information on the organic and inorganic composition, the presence of an active substance or impurities, or the crystalline arrangement of the formulation's compound. After a presentation of these individual techniques, this review puts forward a methodology to combine them. In order to illustrate this approach, examples from the scientific literature (products used for erectile dysfunction treatment, weight loss and malaria) are placed in the centre of the proposed methodology. Combining analytical techniques allows the analyst to conclude on the falsification of a sample, on its compliance in terms of pharmaceutical quality and finally on the safety for patients.
Collapse
Affiliation(s)
- Hervé Rebiere
- French National Agency for Medicines and Health Products Safety, 635 Rue de la Garenne, 34740 Vendargues, France.
| | - Pauline Guinot
- French National Agency for Medicines and Health Products Safety, 635 Rue de la Garenne, 34740 Vendargues, France
| | - Denis Chauvey
- French National Agency for Medicines and Health Products Safety, 635 Rue de la Garenne, 34740 Vendargues, France
| | - Charlotte Brenier
- French National Agency for Medicines and Health Products Safety, 635 Rue de la Garenne, 34740 Vendargues, France
| |
Collapse
|